PDCD1 and neoplasm: For example, in the KEYNOTE-158 study of 9 tumor types leading to pan-solid tumor approval of second-line pembrolizumab (anti-PD-1) in patients with TMB ≥ 10 Muts/Mb by the FoundationOne companion diagnostic (CDx) comprehensive genomic profiling (CGP) device, objective responses were observed in 37%, 13%, and 6% of patients with TMB ≥ 13 Muts/Mb, ≥10 and <13 Muts/Mb, and <10 Muts/Mb, respectively25,26.